Helius Medical Technologies Inc. has filed an updated Prospectus Supplement on July 7, 2025, to offer and sell up to $25 million of its common stock shares through Roth Capital Partners, LLC, as sales agent. This move follows a Sales Agreement entered on June 23, 2023. The shares, registered under the Securities Act of 1933, will be available for sale through various methods, including direct sales on The Nasdaq Global Market. The proceeds from the stock offering are intended to support the company's working capital and general corporate purposes, such as commercialization efforts and research and development activities. Legal counsel for the company, Honigman LLP, has provided an opinion on the shares, which is included as an exhibit in the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.